Conversion to rapamycin in liver transpant recipients with renal insufficiency.
- Author:
Si YU
1
;
Xiao-Shun HE
;
Yi MA
;
An-Bin HU
;
Lin-Wei WU
;
Xiao-Feng ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Calcineurin Inhibitors; Female; Humans; Immunosuppressive Agents; therapeutic use; Liver Transplantation; adverse effects; Male; Middle Aged; Renal Insufficiency; drug therapy; etiology; Retrospective Studies; Sirolimus; therapeutic use; Young Adult
- From: Journal of Southern Medical University 2009;29(11):2276-2278
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the efficacy of conversion from calcineurin-inhibitor (CNI) to rapamycin in liver recipients with CNI-associated renal insufficiency.
METHODSThis retrospective study examined the liver transplant recipients who had switched from CNI to rapamycin between January 2004 and June 2008 in the first affiliated hospital of Sun Yat-sen University. The data of renal function before and after the conversion were analyzed by Wilcoxon sum rank test, and rapamycin-related adverse effects were also observed.
RESULTSCompared with that before conversion, the renal funtion 4 months after the conversion improved significantly (P<0.05). The blood lipid level 3 months after the conversion increased significantly (P<0.05) but were well controlled.
CONCLUSIONRapamycin can be used safely as a good alternative in liver transplant recipients with CNI-related renal insufficiency.
